31
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
Condition(s):Breast NeoplasmsLast Updated:June 29, 2017Unknown status
Fulvestrant: 433 Clinical Trials, Page 4 of 44
Hide Studies Not Open or Pending
32
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
Condition(s):Breast Neoplasm; Hormone Receptor Positive Breast CarcinomaLast Updated:January 20, 2021Recruiting
33
Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer
Condition(s):Carcinoma, Non Small Cell LungLast Updated:October 2, 2015Withdrawn
34
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Condition(s):Ovarian CancerLast Updated:December 28, 2017Completed
35
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Condition(s):Breast CancerLast Updated:July 26, 2022Recruiting
36
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer
Condition(s):Metastatic Breast CancerLast Updated:December 22, 2020Recruiting
37
Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 – Postmenopausal MBC Patients
Condition(s):Metastatic Breast CancerLast Updated:June 15, 2016Unknown status
38
Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients
Condition(s):Breast CancerLast Updated:January 2, 2017Unknown status
39
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
Condition(s):NeoplasmsLast Updated:August 21, 2015Unknown status
40
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
Condition(s):Breast CancerLast Updated:April 24, 2015Completed